Physician profile
Ricki Pollycove
NPI 1013097013
$35,535.26
in general payments reported to CMS, 2019-2025
20 companies · $7,388 in 2025
The $7,388 reported for 2025 was more than what 94% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $19.85 · 2021: $80.71 · 2022: $6,430 · 2023: $19K · 2024: $2,290 · 2025: $7,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Travel and Lodging: $2,758 · Food and Beverage: $2,537 · Consulting Fee: $1,500 · Education: $99.00 · Gift: $1.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,776.50 |
| Travel and Lodging | $2,757.65 |
| Food and Beverage | $2,536.83 |
| Consulting Fee | $1,500.00 |
| Education | $99.00 |
| Gift | $1.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $22,634.88 | 2022-2025 | Veozah |
| Pfizer INC. | $4,820.22 | 2022-2023 | |
| Ascend Therapeutics US, LLC | $4,429.88 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,616.44 | 2025 | |
| Astellas Pharma Global Development | $441.49 | 2023-2025 | Veozah |
| Mayne Pharma Commercial LLC | $348.87 | 2023-2025 | |
| Amag Pharmaceuticals, INC. | $259.11 | 2019 | |
| Therapeuticsmd, INC. | $190.67 | 2019-2022 | |
| Abbvie INC. | $179.48 | 2022-2025 | |
| Intuitive Surgical, INC. | $131.76 | 2025 | |
| Novo Nordisk INC | $129.92 | 2023 | |
| Lilly USA, LLC | $72.90 | 2021-2025 | Mounjaro, Zepbound |
| Ibsa Pharma INC. | $59.18 | 2019-2023 | Tirosint, Licart |
| Myovant Sciences INC. | $46.69 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $45.46 | 2023-2025 | Myfembree |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $31.11 | 2023 | Cologuard Collection Kit |
| Integra Lifesciences Corporation | $27.16 | 2023 | Durasorb Monofilament Mesh |
| Avion Pharmaceuticals | $26.53 | 2022 | |
| Exeltis, USA INC. | $24.25 | 2025 | Slynd |
| Millicent US INC | $19.26 | 2025 | Femring, Intrarosa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ricki Pollycove listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.